Newark, February 7th, 2018 - AvantGen Inc. (San Diego, CA), a world-leading CRO for human and rabbit antibody discovery and optimization, and ACROBiosystems Inc. (Newark, DE), a global biotech company specializing in recombinant protein technology jointly announced the signing of a preferred vendor agreement between the parties. Under the terms of the agreement, AvantGen will enjoy special rate for all ACROBiosystems’ recombinant protein products, including those from its flagship biotinylated protein collection. In addition, ACROBiosystems will also endeavor to develop custom protein products and relevant solutions for AvantGen.
“The principle goal for ACROBiosystems is to better serve the pharmaceutical research community, in particular those involved in therapeutic antibody development. This agreement offers a terrific opportunity for us to work with one of the most innovative antibody discovery CROs. We hope that the variety of platform technologies carried by AvantGen can test the quality, and demonstrate the benefits of ACRO’s protein reagents.” said Mike Chen, the CEO of ACROBiosystems.
“We are pleased to enter this agreement with ACROBiosystems for our recombinant protein needs. In the past years, we have used many different recombinant proteins from ACRObiosystems for novel antibody discovery projects for our clients ranging from large pharmaceutical companies to startup biotech. For cell surface proteins, the antibodies we discovered can readily recognize native proteins on various cells, suggesting these recombinant proteins are of high quality.” said Dr. Xiaomin Fan, CEO of AvantGen.
AvantGen is a San Diego-based antibody discovery and optimization service provider. With its proprietary yeast display system and comprehensive human antibody libraries, AvantGen discovers human antibodies for therapeutic developments for its corporate partners ranging from small biotech to large pharmaceutical companies globally. In addition, AvantGen also generates rabbit monoclonal antibodies for its corporate partners for target validation and PK studies. Many of AvantGen’s clients have used ACROBiosystems’s recombinant proteins for novel antibody discoveries successfully.
ACROBiosystems is a leading recombinant protein manufacturer specializing in human cell-based platform technologies. The company carries a catalog of over 1,000 high quality products that are specifically designed for pharmaceutical assay development. The portfolio features the exclusive MABSol® biotinylated protein collection built upon AvitagTM technology. These reagents are uniquely suitable for Biacore, AlphaLisa, MSD, among other established assay platforms. ACROBiosystems provides protein supplies to over 2,000 customers worldwide, including those from pharmaceutical companies, CROs, and non-profit research organizations.
This web search service is supported by Google Inc.